Lipoproteins, Platelets and Atherothrombosis;Lipoproteínas, plaquetas y aterotrombosis

Revista Espanola de Cardiologia

Volumn 62, Issue 10, 2009, Pages 1161-1178

  Badimón, Lina ^a,b,c   Vilahur, Gemma ^a,b   Padró, Teresa ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Low density lipoprotein; Platelets; Resident vascular cells

Indexed keywords

GELATINASE B; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CELL; CELL INTERACTION; ENDOTHELIAL DYSFUNCTION; FOAM CELL; HUMAN; MACROPHAGE; PATHOGENESIS; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOGENICITY; THROMBOSIS; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; LIPOPROTEINS, LDL; THROMBOSIS;

EID: 70349764454     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)72385-1     Document Type: Article

References (136)

1. Yusuf S., Reddy S., Ounpuu S., and Anand S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 (2001) 2746-2753
2. Gleissner C.A., Leitinger N., and Ley K. Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis. Hypertension 50 (2007) 276-283
3. Llorente-Cortes V., and Badimón L. LDL receptor-related protein and the vascular wall: Implications for atherothrombosis. Arterioscler Thromb Vasc Biol 25 (2005) 497-504
4. Michiels C. Endothelial cell functions. J Cell Physiol 196 (2003) 430-443
5. Khazaei M., Moien-Afshari F., and Laher I. Vascular endothelial function in health and diseases. Pathophysiology 15 (2008) 49-67
6. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: Basic and clinical aspects. Arterioscler Thromb Vasc Biol 22 (2002) 539-548
7. Orr A.W., Stockton R., Simmers M.B., Sanders J.M., Sarembock I.J., Blackman B.R., et al. Matrix-specific p21-activated kinase activation regulates vascular permeability in atherogenesis. J Cell Biol 176 (2007) 719-727
8. Fryer B.H., Wang C., Vedantam S., Zhou G.L., Jin S., Fletcher L., et al. CGMP-dependent protein kinase phosphorylates p21-activated kinase (pak) 1, inhibiting pak/nck binding and stimulating pak/vasodilator-stimulated phosphoprotein association. J Biol Chem 281 (2006) 11487-11495
9. Bevilacqua M.P., Pober J.S., Majeau G.R., Fiers W., Cotran R.S., and Gimbrone Jr. M.A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 83 (1986) 4533-4537
10. De Caterina R.M.C. Inflammation in early atherogenesis: Impact of ace inhibition. Eur Heart J 5 Suppl A (2003) A15-A24
11. Chadjichristos C.E., and Kwak B.R. Connexins: New genes in atherosclerosis. Ann Med 39 (2007) 402-411
12. Georgescu A., Alexandru N., Constantinescu E., and Popov D. Effect of gap junction uncoupler heptanol on resistance arteries reactivity in experimental models of diabetes, hyperlipemia and hyperlipemia-diabetes. Vascul Pharmacol 44 (2006) 513-518
13. Vidal F., Colome C., Martínez-González J., and Badimón L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mrna and protein levels in endothelial cells. Eur J Biochem 252 (1998) 378-384
14. Liao J.K., Shin W.S., Lee W.Y., and Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270 (1995) 319-324
15. Pritchard Jr. K.A., Groszek L., Smalley D.M., Sessa W.C., Wu M., Villalon P., et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 77 (1995) 510-518
16. Cai H. Nad(p)h oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 96 (2005) 818-822
17. Schmidt T.S., and Alp N.J. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 113 (2007) 47-63
18. Oorni K., Pentikainen M.O., Ala-Korpela M., and Kovanen P.T. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: Molecular mechanisms and effects on matrix interactions. J Lipid Res 41 (2000) 1703-1714
19. Camejo G., Hurt-Camejo E., Wiklund O., and Bondjers G. Association of apo b lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 139 (1998) 205-222
20. Llorente-Cortes V., Otero-Vinas M., Sanchez S., Rodriguez C., and Badimón L. Low-density lipoprotein upregulates lowdensity lipoprotein receptor-related protein expression in vascular smooth muscle cells: Possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation 106 (2002) 3104-3110
21. Barnes M.J., and Farndale R.W. Collagens and atherosclerosis. Exp Gerontol 34 (1999) 513-525
22. Rekhter M.D. Collagen synthesis in atherosclerosis: Too much and not enough. Cardiovasc Res 41 (1999) 376-384
23. Llorente-Cortes V., Martínez-González J., and Badimón L. LDL receptor-related protein mediates uptake of aggregated ldl in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20 (2000) 1572-1579
24. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., et al. The multiple roles of macrophage scavenger receptors (MSR) in vivo: Resistance to atherosclerosis and susceptibility to infection in msr knockout mice. J Atheroscler Thromb 4 (1997) 1-11
25. Saad A.F., Virella G., Chassereau C., Boackle R.J., and Lopes-Virella M.F. OxLDL immune complexes activate complement and induce cytokine production by monomac 6 cells and human macrophages. J Lipid Res 47 (2006) 1975-1983
26. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
27. Horstman L.L., Jy W., Jiménez J.J., and Ahn Y.S. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 9 (2004) 1118-1135
28. Kinlay S., Libby P., and Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 12 (2001) 383-389
29. Csiszar A., Wang M., Lakatta E.G., and Ungvari Z. Inflammation and endothelial dysfunction during aging: Role of nf-kappab. J Appl Physiol 105 (2008) 1333-1341
30. Mine S., Tabata T., Wada Y., Fujisaki T., Iida T., Noguchi N., et al. Oxidized low density lipoprotein-induced lfa-1-dependent adhesion and transendothelial migration of monocytes via the protein kinase c pathway. Atherosclerosis 160 (2002) 281-288
31. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 27 (2007) 266-274
32. Buton X., Mamdouh Z., Ghosh R., Du H., Kuriakose G., Beatini N., et al. Unique cellular events occurring during the initial interaction of macrophages with matrix-retained or methylated aggregated low density lipoprotein (LDL). Prolonged cell-surface contact during which ldl-cholesteryl ester hydrolysis exceeds ldl protein degradation. J Biol Chem 274 (1999) 32112-32121
33. Kruth H.S. Sequestration of aggregated low-density lipoproteins by macrophages. Curr Opin Lipidol 13 (2002) 483-488
34. Morita S.Y., Kawabe M., Sakurai A., Okuhira K., Vertut-Doi A., Nakano M., et al. Ceramide in lipid particles enhances heparan sulfate proteoglycan and low density lipoprotein receptor-related protein-mediated uptake by macrophages. J Biol Chem 279 (2004) 24355-24361
35. Llorente-Cortes V., Royo T., Otero-Vinas M., Berrozpe M., and Badimón L. Sterol regulatory element binding proteins downregulate ldl receptor-related protein (lrp1) expression and lrp1-mediated aggregated ldl uptake by human macrophages. Cardiovasc Res 74 (2007) 526-536
36. Butt E., Gambaryan S., Gottfert N., Galler A., Marcus K., and Meyer H.E. Actin binding of human lim and sh3 protein is regulated by cgmp- and camp-dependent protein kinase phosphorylation on serine 146. J Biol Chem 278 (2003) 15601-15607
37. Schwartz D., Peterson O.W., Mendonca M., Satriano J., Lortie M., and Blantz R.C. Agmatine affects glomerular filtration via a nitric oxide synthase-dependent mechanism. Am J Physiol 272 (1997) F597-601
38. Han C.I., Campbell G.R., and Campbell J.H. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 38 (2001) 113-119
39. Ulrich P., and Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 56 (2001) 1-21
40. Li H., Liang J., Castrillon D.H., DePinho R.A., Olson E.N., and Liu Z.P. Foxo4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 27 (2007) 2676-2686
41. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
42. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein e-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 109 (2004) 1408-1414
43. Levi M., Moons L., Bouche A., Shapiro S.D., Collen D., and Carmeliet P. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 103 (2001) 2014-2020
44. Carlin S.M., Resink T.J., Tamm M., and Roth M. Urokinase signal transduction and its role in cell migration. FASEB J 19 (2005) 195-202
45. Jiang M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., et al. Ang II-stimulated migration of vascular smooth muscle cells is dependent on lr11 in mice. J Clin Invest 118 (2008) 2733-2746
46. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 383 (2002) 5-19
47. Padró T, Peña E, Badimón L. Effects of low density lipoproteins on the sub-cellular distribution pattern of upa/upar in migrating human coronary vascular smooth muscle cells. XIX Intern Congress on Fibrinolysis and Thrombolysis.
48. Padro T., Pena E., Garcia-Arguinzonis M., Llorente-Cortes V., and Badimón L. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc Res 77 (2008) 211-220
49. Presta M., Camozzi M., Salvatori G., and Rusnati M. Role of the soluble pattern recognition receptor ptx3 in vascular biology. J Cell Mol Med 11 (2007) 723-738
50. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
51. Badimón L., and Vilahur G. Platelets, arterial thrombosis and cerebral ischemia. Cerebrovasc Dis 24 Suppl 1 (2007) 30-39
52. Badimón L., Badimón J.J., Vilahur G., Segales E., and Llorente V. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 32 (2002) 225-231
53. Relou I.A., Hackeng C.M., Akkerman J.W., and Malle E. Lowdensity lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 60 (2003) 961-971
54. Tandon N.N., Kralisz U., and Jamieson G.A. Identification of glycoprotein IV (CD36) as a primary receptor for plateletcollagen adhesion. J Biol Chem 264 (1989) 7576-7583
55. Engelmann B., Kogl C., Kulschar R., and Schaipp B. Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low- and high-density lipoprotein to human platelets. Biochem J 315 (1996) 781-789
56. + influx in human platelets. J Biol Chem 275 (2000) 19159-19166
57. Jin R.C., Voetsch B., and Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation 12 (2005) 247-258
58. Moncada S. Adventures in vascular biology: A tale of two mediators. Philos Trans R Soc Lond B Biol Sci 361 (2006) 735-759
59. Duran X., Sanchez S., Vilahur G., and Badimón L. Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. J Thromb Haemost 6 (2008) 1385-1392
60. Marcus A.J., Broekman M.J., Drosopoulos J.H., Olson K.E., Islam N., Pinsky D.J., et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 31 (2005) 234-246
61. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196 (2002) 887-896
62. Massberg S., Gruner S., Konrad I., García Arguinzonis M.I., Eigenthaler M., Hemler K., et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 103 (2004) 136-142
63. Nityanand S., Pande I., Bajpai V.K., Singh L., Chandra M., and Singh B.N. Platelets in essential hypertension. Thromb Res 72 (1993) 447-454
64. Broijersen A., Karpe F., Hamsten A., Goodall A.H., and Hjemdahl P. Alimentary lipemia enhances the membrane expression of platelet p-selectin without affecting other markers of platelet activation. Atherosclerosis 137 (1998) 107-113
65. Nowak J., Murray J.J., Oates J.A., and FitzGerald G.A. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 76 (1987) 6-14
66. Manduteanu I., Calb M., Lupu C., Simionescu N., and Simionescu M. Increased adhesion of human diabetic platelets to cultured valvular endothelial cells. J Submicrosc Cytol Pathol 24 (1992) 539-547
67. Huo Y., and Ley K.F. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14 (2004) 18-22
68. Stenberg P., McEver R., Shuman M., Jacques Y., and Bainton D.F. A platelet alpha granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 101 (1985) 880-886
69. Furman M.I., Benoit S.E., Barnard M.R., Valeri C.R., Borbone M.L., Becker R.C., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol (1998) 352-358
70. Badimón J.J., Fuster V., Chesebro J.H., and Badimón L. Coronary atherosclerosis. A multifactorial disease. Circulation 87 (1993) II3-II16
71. Badimón L., and Vilahur G. Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. Rev Esp Cardiol 61 (2008) 501-513
72. Davies M.J., and Thomas A.C. Plaque fissuring -the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53 (1985) 363-373
73. Ruggeri Z.M., and Mendolicchio G.L. Adhesion mechanisms in platelet function. Circ Res 100 (2007) 1673-1685
74. Ruggeri Z.M. Von Willebrand factor. J Clin Invest 99 (1997) 559-564
75. Savage B., Saldivar E., and Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von willebrand factor. Cell 84 (1996) 657-666
76. Ruggeri Z.M. Role of von Willebrand factor in platelet thrombus formation. Ann Med 32 Suppl 1 (2000) 2-9
77. Massberg S., Shulz C., and Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 3 (2003) 147-161
78. Gibbins J., Okuma M., Farndale R., Barnes M., and Watson S. Glicoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the FC receptor gamma-chain. FEBS Lett 413 (1997) 255-259
79. Nieswandt B., Brakebush C., and Bergmeier W.E.A. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20 (2001) 2120-2130
80. Saelman E.U., Nieuwenhuis H.K., Hese K.M., De Groot P.G., Heijnen H.F., Sage E.H., et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood 83 (1994) 1244-1250
81. Kolodgie F.D., Gold H.K., Burke A.P., Fowler D.R., Kruth H.S., Weber D.K., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349 (2003) 2316-2325
82. Sevitt S. Platelets and foam cells in the evolution of atherosclerosis. Histological and immunohistological studies of human lesions. Atherosclerosis 61 (1986) 107-115
83. Daub K., Langer H., Seizer P., Stellos K., May A.E., Goyal P., et al. Platelets induce differentiation of human cd34+ progenitor cells into foam cells and endothelial cells. FASEB J 20 (2006) 2559-2561
84. Chandler A.B., and Hand R.A. Phagocytized platelets: A source of lipids in human thrombi and atherosclerotic plaques. Science 134 (1961) 946-947
85. Fuster V., Badimón L., Badimón J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 (1992) 310-318
86. Llorente-Cortes V., Otero-Vinas M., Berrozpe M., and Badimón L. Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries. Eur J Clin Invest 34 (2004) 182-190
87. García-Arguinzonis M., Padró T., Llorente-Cortes V., and Badimón L. Effect LDL negatively regulate HSP 27 phosphorylation in human vascular smooth muscle cells (2007), European Atherosclerosis Society, Helsinki
88. Otero-Viñas M., Llorente-Cortes V., Pena E., Padro T., and Badimón L. Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells. Atherosclerosis 194 (2007) 326-333
89. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernández-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
90. Schecter A.D., Spirn B., Rossikhina M., Giesen P.L., Bogdanov V., Fallon J.T., et al. Release of active tissue factor by human arterial smooth muscle cells. Circ Res 87 (2000) 126-132
91. Diamant M., Nieuwland R., Pablo R.F., Sturk A., Smit J.W., and Radder J.K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106 (2002) 2442-2447
92. Camino-Lopez S., Llorente-Cortes V., Sendra J., and Badimón L. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and rho a translocation in human vascular smooth muscle cells. Cardiovasc Res 73 (2007) 208-216
93. Llorente-Cortes V., Otero-Viñas M., Camino-Lopez S., Llampayas O., and Badimón L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 110 (2004) 452-459
94. De Lorgeril M., Renaud S., Mamelle N., Salen P., Martin J.L., Monjaud I., et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343 (1994) 1454-1459
95. Hamik A., Setiadi H., Bu G., McEver R.P., and Morrissey J.H. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 274 (1999) 4962-4969
96. Cattaneo M., and Gachet C. Adp receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 192 (1999) 2281-2285
97. Jin J., Quinton T., Zhang J., Rittenhouse S., and Kunapuli S. Adenosin diphosphate induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin alpha IIb beta 3 and ADP receptors. Blood 99 (2000) 193-198
98. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the european society of cardiology. Eur Heart J 25 (2004) 166-181
99. Vilahur G., Casani L., and Badimón L. A thromboxane A2/prostaglandin H2 receptor antagonist (s18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 98 (2007) 662-669
100. Viles-González J.F., Fuster V., Corti R., Valdiviezo C., Hutter R., Corda S., et al. Atherosclerosis regression and tp receptor inhibition: Effect of s18886 on plaque size and composition -a magnetic resonance imaging study. Eur Heart J 26 (2005) 1557-1561
101. Sims P.J., and Wiedmer T. Unravelling the mysteries of phospholipid scrambling. Thromb Haemost 86 (2001) 214-221
102. Badimón L., Chesebro J.H., and Badimón J.J. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 86 (1992) III74-III85
103. Cho J., and Mosher D.F. Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood 107 (2006) 3555-3563
104. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernández-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
105. Moons A., Levi M., and Peters R. Tissue factor and coronary artery disease. Cardiovasc Res 53 (2002) 313-325
106. Viles-González J.F., Fuster V., and Badimón J.J. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 6 (2006) 489-499
107. Viles-Gonzalez J.F.A.S., Valdiviezo C., Zafar M.U., Hutter R., Sanz J., Rius T., et al. Update in atherothrombotic disease. Mt Sinai J Med 71 (2004) 197-208
108. Lefkovits J., and Topol E. Role of platelet inhibitor agents in coronary artery disease. In: Topol E.J. (Ed). Textbook of interventional cardiology (1999), Saunders, Philadelphia 3-24
109. Peterson E.D., Pollack Jr. C.V., Roe M.T., Parsons L.S., Littrell K.A., Canto J.G., et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: Observations from the national registry of myocardial infarction 4. J Am Coll Cardiol 42 (2003) 45-53
110. Vu T.K., Hung D.T., Wheaton V.I., and Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 (1991) 1057-1068
111. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103 (1999) 879-887
112. VanWijk M.J., VanBavel E., Sturk A., and Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 59 (2003) 277-287
113. Sims P.J., Faioni E.M., Wiedmer T., and Shattil S.J. Complement proteins c5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor va and express prothrombinase activity. J Biol Chem 263 (1988) 18205-18212
114. Tan K.T., Tayebjee M.H., Lynd C., Blann A.D., and Lip G.Y. Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med 37 (2005) 61-66
115. Nomura S., Tandon N.N., Nakamura T., Cone J., Fukuhara S., and Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 158 (2001) 277-287
116. Forlow S.B., McEver R.P., and Nollert M.U. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 95 (2000) 1317-1323
117. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
118. Ross R. Atherosclerosis -an inflammatory disease. N Engl J Med 340 (1999) 115-126
119. Mause S.F., Von Hundelshausen P., Zernecke A., Koenen R.R., and Weber C. Platelet microparticles: A transcellular delivery system for rantes promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25 (2005) 1512-1518
120. Pfister S.L. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension 43 (2004) 428-433
121. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333 (1995) 1301-1307
122. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s). Lancet. 1994;344:1383-9.
123. Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 29 (2008) 2625-2633
124. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA 295 (2006) 1556-1565
125. Nozue T., Yamamoto S., Tohyama S., Umezawa S., Kunishima T., Sato A., et al. Treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (truth study): Rationale and design. Circ J 73 (2009) 352-355
126. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-5.
127. Kinlay S., and Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 98 (2006) P2-P8
128. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 98 (2006) P9-P17
129. Libby P., and Sasiela W. Plaque stabilization: Can we turn theory into evidence?. Am J Cardiol 98 (2006) P26-P33
130. Badimón J.J., Badimón L., Turitto V.T., and Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb 11 (1991) 395-402
131. Dangas G., Badimón J.J., Smith D.A., Unger A.H., Levine D., Shao J.H., et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 33 (1999) 1294-1304
132. Alonso R., Mata P., De Andres R., Villacastin B.P., Martinez-Gonzalez J., and Badimón L. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 157 (2001) 423-429
133. Alfon J., Pueyo Palazon C., Royo T., and Badimón L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 81 (1999) 822-827
134. Casani L., Sanchez-Gomez S., Vilahur G., and Badimón L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 94 (2005) 1035-1041
135. Vilahur G, Casani L, Pena E, Duran X, Juan-Babot O, Badimón L. Induction of risk by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis. 2009 [en prensa].
136. Di Sciascio G., Patti G., Pasceri V., Gaspardone A., Colonna G., and Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol (2009) DOI: 10.1016/j. jacc.2009.05.028 [E-pub 1 Jul 2009]